Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (cohort visit planners) and reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
- We will ring you to check your suitability and provide further information about the study
- We will make you a screening appointment at NZCR Auckland. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
New Zealand Clinical Research is trialling an investigational medication that is being developed for the treatment of complement-mediated disease.
ARO-CFB is being developed for the treatment of complement-mediated disease. The complement system, also known as the complement cascade, is a part of the immune system that enhances (complements) the immunity by providing a first line of defence to help fight against infections.
It is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
This study (2023 FULL 19233) is being funded by Atai Therapeutics Pty. Ltd. and has been approved by the Health and Disability Ethics Committee.
Study Candidates
- Healthy Males and Females
- Age 18 – 60 years old
- BMI 18 – 35 kg/m2 (inclusive)
- Smokers allowed
What is Involved?
Inpatient stay: 2-night stay
Follow-up visits: 13 follow-up visits
Reimbursement: $4,750 (less tax)